Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations.

Yoshiyuki SueharaDeepu AlexAnita S BowmanSumit MiddhaAhmet ZehirDebyani ChakravartyLu WangGeorge JourKhedoudja NafaTakuo HayashiAchim A JungbluthDenise FrosinaEmily K SlotkinNeerav ShuklaPaul A MeyersJohn H HealeyMeera HameedMarc Ladanyi

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

We found potentially clinically actionable alterations in approximately 21% of patients with osteosarcoma. In addition, at least 40% of patients have tumors harboring PDGFRA or VEGFA amplification, representing candidate subsets for clinical evaluation of additional therapeutic options. We propose a new genomically based algorithm for directing patients with osteosarcoma to clinical trial options.

Keyphrases

clinical trial
end stage renal disease
chronic kidney disease
newly diagnosed
peripheral blood
machine learning
prognostic factors
single cell
patient reported
phase ii